Re: Name 3 things this CEO has accomplished in the last 3 year's?
|
5
|
Resverlogix Corp.
|
Nov 29, 2023 08:19PM
|
Re: The MD@A for the period ending July 31, 2017
|
5
|
Resverlogix Corp.
|
Sep 15, 2017 08:50AM
|
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
|
5
|
Resverlogix Corp.
|
Jan 18, 2022 08:06AM
|
Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
5
|
Resverlogix Corp.
|
Aug 15, 2017 07:14AM
|
Re: Leading From Behind
|
5
|
Resverlogix Corp.
|
Oct 14, 2020 10:38AM
|
Re: What's the deal?
|
5
|
Resverlogix Corp.
|
Nov 29, 2020 09:28AM
|
Re: Epizyme market cap $750 mil USd
|
5
|
Zenith Epigenetics
|
Jun 15, 2017 09:53PM
|
Re: Sneaking Suspicion...
|
5
|
Resverlogix Corp.
|
Feb 04, 2021 09:55PM
|
Re: The MD@A for the period ending July 31, 2017
|
4
|
Resverlogix Corp.
|
Sep 14, 2017 08:02AM
|
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
4
|
Resverlogix Corp.
|
Oct 04, 2023 08:44AM
|
RVX…The Hawthorne Effect
|
4
|
Resverlogix Corp.
|
Oct 01, 2022 11:18AM
|
Re: AGM attendance
|
4
|
Resverlogix Corp.
|
May 24, 2022 08:37PM
|
Re: Trials and statistics, next steps
|
4
|
Resverlogix Corp.
|
Feb 11, 2020 03:58PM
|
Re: Looks like 0 participation in warrant incentive imo - answer to my email...
|
4
|
Resverlogix Corp.
|
Jan 18, 2020 04:48PM
|
Re: Potential Scope of Indications for Apabetalone (selective BRD/BD inhibition)
|
4
|
Resverlogix Corp.
|
Nov 14, 2022 06:49PM
|
Re: Forward looking statements...
|
4
|
Resverlogix Corp.
|
Feb 05, 2021 09:59AM
|
Re: https://themarkether...
|
4
|
Resverlogix Corp.
|
Mar 01, 2022 09:49PM
|
Re: Long Covid thought to affect half of Covid cases
|
4
|
Resverlogix Corp.
|
Jun 24, 2021 06:56PM
|
Re: Rant time...
|
4
|
Resverlogix Corp.
|
Feb 05, 2021 10:37AM
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
4
|
Resverlogix Corp.
|
Aug 04, 2020 04:03PM
|